Literature DB >> 10732742

Analysis of radon-associated squamous cell carcinomas of the lung for a p53 gene hotspot mutation.

Q Yang1, H Wesch, K M Mueller, H Bartsch, K Wegener, M Hollstein.   

Abstract

Squamous cell lung carcinomas (SCC) from former employees of the Wismut uranium mining company (Saxony, Germany) were obtained from the Stollberg Archive in order to screen for p53 tumour suppressor gene codon 249 arg-->met hotspot mutations, a putative molecular bio-dosimeter of alpha-particle (radon) exposure (Taylor et al (1994) Lancet 343: 86-87; McDonald et al (1995) Cancer Epidemiol Biomarkers Prevent 4: 791-793). Of the 29 archived samples of SCC meeting quality criteria for DNA analysis by polymerase chain reaction (PCR) and Haelll restriction enzyme digestion, two tumours were found that harboured this mutation. DNA sequencing confirmed the presence of a G to T base substitution within the Haelll site spanning codons 249 and 250 of the p53 gene that results in replacement of arginine (wild-type) by methionine at residue 249. When these data are combined with those from our previous study of tumours from the Stollberg Archive in which 50 lung tumours were examined, (including nine SCCs), we conclude that the G-->T (arg-->met) codon 249 mutation prevalence in the Wismut miner cohort is not sharply elevated in lung cancers in general (two mutations/79 tumours), or specifically in SCCs of the lung (two mutations/38 SCC) when compared to data from lung cancer patients with no reported occupational exposure to radon gas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10732742      PMCID: PMC2374385          DOI: 10.1054/bjoc.1999.0995

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Screening for putative radon-specific p53 mutation hotspot in German uranium miners.

Authors:  H Bartsch; M Hollstein; R Mustonen; J Schmidt; A Spiethoff; H Wesch; T Wiethege; K M Müller
Journal:  Lancet       Date:  1995-07-08       Impact factor: 79.321

2.  Screening for codon 249 p53 mutation in lung cancer associated with domestic radon exposure.

Authors:  Y M Lo; S Darby; L Noakes; E Whitley; P B Silcocks; K A Fleming; J I Bell
Journal:  Lancet       Date:  1995-01-07       Impact factor: 79.321

3.  Schneeberg lung disease and uranium mining in the Saxon Ore Mountains (Erzgebirge).

Authors:  W Schüttmann
Journal:  Am J Ind Med       Date:  1993-02       Impact factor: 2.214

4.  53 mutation hotspot in radon-associated lung cancer.

Authors:  T K Hei; J Bedford; C A Waldren
Journal:  Lancet       Date:  1994-05-07       Impact factor: 79.321

5.  Radon, mycotoxins, p53, and uranium mining.

Authors:  S Venitt; P J Biggs
Journal:  Lancet       Date:  1994-03-26       Impact factor: 79.321

Review 6.  Clinical implications of the p53 gene.

Authors:  D Sidransky; M Hollstein
Journal:  Annu Rev Med       Date:  1996       Impact factor: 13.739

7.  p53 gene mutation analysis in tumors of patients exposed to alpha-particles.

Authors:  M Hollstein; H Bartsch; H Wesch; E H Kure; R Mustonen; K R Mühlbauer; A Spiethoff; K Wegener; T Wiethege; K M Müller
Journal:  Carcinogenesis       Date:  1997-03       Impact factor: 4.944

8.  IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools.

Authors:  P Hainaut; T Hernandez; A Robinson; P Rodriguez-Tome; T Flores; M Hollstein; C C Harris; R Montesano
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

9.  Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners.

Authors:  K H Vähäkangas; J M Samet; R A Metcalf; J A Welsh; W P Bennett; D P Lane; C C Harris
Journal:  Lancet       Date:  1992-03-07       Impact factor: 79.321

10.  p53 mutation hotspot in radon-associated lung cancer.

Authors:  J A Taylor; M A Watson; T R Devereux; R Y Michels; G Saccomanno; M Anderson
Journal:  Lancet       Date:  1994-01-08       Impact factor: 79.321

View more
  3 in total

1.  Targeting the Akt/mTOR pathway in Brca1-deficient cancers.

Authors:  T Xiang; Y Jia; D Sherris; S Li; H Wang; D Lu; Q Yang
Journal:  Oncogene       Date:  2011-01-17       Impact factor: 9.867

Review 2.  Lung cancer in never smokers: molecular profiles and therapeutic implications.

Authors:  Charles M Rudin; Erika Avila-Tang; Curtis C Harris; James G Herman; Fred R Hirsch; William Pao; Ann G Schwartz; Kirsi H Vahakangas; Jonathan M Samet
Journal:  Clin Cancer Res       Date:  2009-09-15       Impact factor: 12.531

Review 3.  The cellular and molecular carcinogenic effects of radon exposure: a review.

Authors:  Aaron Robertson; James Allen; Robin Laney; Alison Curnow
Journal:  Int J Mol Sci       Date:  2013-07-05       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.